Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

SQZ Biotechnologies Co (SQZ) USD0.001

Sell:$14.44 Buy:$14.53 Change: $0.04 (0.00%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Change: $0.04 (0.00%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Change: $0.04 (0.00%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. It uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in highly immunogenic (HPV) plus tumors. It is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating robust (cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that has been designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.

Contact details

200 Arsenal Yards Blvd., Ste. 210
United States
+1 (617) 7588672

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$406.13 million
Shares in issue:
28.05 million
New York Stock Exchange
United States
US dollar

Key personnel

  • Amy Schulman
    Chairman of the Board
  • Armon Sharei
    President, Chief Executive Officer, Founder, Director
  • Teri Loxam
    Chief Financial Officer
  • David First
    Chief People Officer
  • Howard Bernstein
    Chief Scientific Officer
  • Lawrence Knopf
    General Counsel
  • Oliver Rosen
    Chief Medical Officer
  • Micah Zajic
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.